Has Dimitri Belkin, MD received payments from drug or device companies?

Yes. Drug and device makers reported $2,124 in general payments to Dimitri Belkin, MD across 66 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Dimitri Belkin, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Dimitri Belkin, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Dimitri Belkin, MD

Internal Medicine · Philadelphia, PANPI 1861856155

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.5% of the total across 66 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 22.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,386, more than ten times the $13 reported in 2021.

$2,124in general payments, 2019–2025

Across 66 payments — averaging $32.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$466
Johnson & Johnson$235
Takeda Pharmaceuticals U.S.A., Inc.$225
Gilead$217
Regeneron Healthcare Solutions, Inc.$134
Boston Scientific$126
plus $720 from 14 others

What the payments were for

Food & beverage$2,09399%
Education$311%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie	18	$466
Johnson & Johnson	5	$235
Takeda Pharmaceuticals U.S.A., Inc.	6	$225
Gilead	5	$217
Regeneron Healthcare Solutions, Inc.	4	$134
Boston Scientific	1	$126
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	5	$122
Fujifilm Healthcare Americas Corporation	1	$113
Phathom Pharmaceuticals, Inc.	4	$108
Ipsen Biopharmaceuticals, Inc	2	$63
Lilly USA, LLC	3	$61
Intercept Pharmaceuticals, Inc.	2	$55
Merck	2	$38
Bristol Myers Squibb	2	$34
Pfizer	1	$31
Sanofi	1	$28
Ferring Pharmaceuticals Inc.	1	$20
Madrigal Pharmaceuticals	1	$19
Lucid Diagnostics Inc.	1	$16
Apollo Endosurgery US Inc	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,124 in reported general payments places this provider in the 85th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania →

Medicare billing

Part B allowed, 2024

$21,213

Medicare patients

115

Services billed

153

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg	68	$1,364
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates	14	$789
Pantoprazole Sodium	41	$514
Omeprazole	27	$324
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl	22	$307
Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl	14	$238
Gavilyte-NSodium Chloride/Nahco3/Kcl/Peg	16	$220
Carvedilol	18	$133

Paid to pharmacies, not to this prescriber.

Other internal medicine in Philadelphia

Jonathan EpsteinPhiladelphia$13.1M
Pitamber DevgonPhiladelphia$7.5M
Daniel RaderPhiladelphia$1.7M
David GoldmannPhiladelphia$525K
Eyob FeyssaPhiladelphia$328K
Emil AbramianPhiladelphia$199K
Michael KnightPhiladelphia$178K
James BlakePhiladelphia$164K
Gina SimonciniPhiladelphia$158K
James LewisPhiladelphia$106K

See the full list for Pennsylvania →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →